Corona vaccine study Novavax is 90 percent effective
Status: 14.06.2021 2:21 p.m. According to preliminary study data, the corona vaccine from the US pharmaceutical manufacturer Novavax is safe and highly effective – even with virus variants. The product raises great hopes, especially in developing countries. According to the US pharmaceutical company, the Novavax corona vaccine protects well against the virus and its variants. The company said that the vaccine was around 90 percent effective and, according to preliminary data from a study, safe. The vaccine effectiveness study involved nearly 30,000 people in the United States and Mexico. Two-thirds of them received two doses of the vaccine three weeks apart, all others received placebos. A total of 77 people were infected with the coronavirus, 14 of them in the group of those who were vaccinated. Of the participants who received the drug, none developed severe or moderate symptoms, while there were 14 in the comparison group without vaccination.
Corona vaccine Which slows down vaccine production Corona vaccine is still scarce. What makes it so difficult to manufacture quickly in large quantities?
No cases of blood clots or heart problems
The vaccine was similarly effective against several variants of the coronavirus, including the alpha variant first discovered in the UK, as well as in high-risk groups such as the elderly and people with pre-existing conditions. The side effects were similar to those of other vaccines and mainly concerned pain at the injection site. There have been no reports of blood clots or heart problems, said Novavax boss Stanley Erck. Novavax plans to publish the results in a medical journal where they will be reviewed by independent experts.
Vaccine important for developing countries
The company said that applications for approval would be submitted in the USA and Europe, among others, by the end of September. Until then, a production of 100 million cans per month is possible. Novavax’s vaccine is easy to transport and store, which is why it is expected to play an important role in vaccination campaigns in developing countries. “Many of our first doses will go to low- and middle-income countries, and that was the goal from the start,” said Erck. Novavax’s vaccine works in a similar way to flu vaccines. It is made with laboratory-grown copies of the spike protein that envelops the coronavirus. The immune system reacts to the proteins in the vaccine and is thus prepared when it is actually confronted with the virus. Other vaccines that are widely used today contain the genetic instructions for the body to make its own spike protein.
Corona vaccine African countries are back in line again Far too little vaccine, plus wars and conflicts – the vaccination campaigns in the countries of Africa are not getting off the ground.